Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3579]

Five key factors predict the response of cancer patients to immunotherapy

Five key factors predict the response of cancer patients to immunotherapy

ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer

ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer

Using a molecular scissors to improve CAR-T cell therapy

Using a molecular scissors to improve CAR-T cell therapy

ESMO 2024: Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial

ESMO 2024: Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial

Risk of secondary cancers after CAR T therapy may be similar to risk after other cancer treatments

Risk of secondary cancers after CAR T therapy may be similar to risk after other cancer treatments

Five key factors predict the response of cancer patients to immunotherapy

Five key factors predict the response of cancer patients to immunotherapy

WCLC 2024: LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met protein-overexpressing EGFR WT nonsquamous NSCLC

WCLC 2024: LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met...

Double trouble for triple-negative breast cancer

Double trouble for triple-negative breast cancer

How the scars of demolished brain tumours seed relapse

How the scars of demolished brain tumours seed relapse

WCLC 2024: Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive advanced NSCLC in HARMONi-2 study

WCLC 2024: Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive...

More from ecancer